Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression.
about
The fate of chemoresistance in triple negative breast cancer (TNBC)Epigenetic Therapy for Solid Tumors: Highlighting the Impact of Tumor HypoxiaChemoresistance, cancer stem cells, and miRNA influences: the case for neuroblastomaThe role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapyANGPTL4 induction by prostaglandin E2 under hypoxic conditions promotes colorectal cancer progressionPromotion of a cancer-like phenotype, through chronic exposure to inflammatory cytokines and hypoxia in a bronchial epithelial cell line modelTumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancerTherapeutic efficacy and safety of paclitaxel/lonidamine loaded EGFR-targeted nanoparticles for the treatment of multi-drug resistant cancerHypoxia-induced modulation of apoptosis and BCL-2 family proteins in different cancer cell typesSmall Molecule Inhibition of miR-544 Biogenesis Disrupts Adaptive Responses to Hypoxia by Modulating ATM-mTOR SignalingUsing Stable Free Radicals to Obtain Unique and Clinically Useful Data In Vivo in Human Subjects.Tumor vascular changes mediated by inhibition of oncogenic signaling.Molecular mechanisms of hypoxia in cancer.Anti-viral state segregates two molecular phenotypes of pancreatic adenocarcinoma: potential relevance for adenoviral gene therapyAutophagy inhibits chemotherapy-induced apoptosis through downregulating Bad and Bim in hepatocellular carcinoma cells.Cancer associated fibroblasts and tumor growth: focus on multiple myelomaTumor cycling hypoxia induces chemoresistance in glioblastoma multiforme by upregulating the expression and function of ABCB1TMEM45A is essential for hypoxia-induced chemoresistance in breast and liver cancer cellsSurvival of cancer stem cells under hypoxia and serum depletion via decrease in PP2A activity and activation of p38-MAPKAPK2-Hsp27.Role of hypoxia and glycolysis in the development of multi-drug resistance in human tumor cells and the establishment of an orthotopic multi-drug resistant tumor model in nude mice using hypoxic pre-conditioning.Anti-apoptotic role of HIF-1 and AP-1 in paclitaxel exposed breast cancer cells under hypoxiaSingle-cell analysis reveals early manifestation of cancerous phenotype in pre-malignant esophageal cells.F-18 fluoromisonidazole for imaging tumor hypoxia: imaging the microenvironment for personalized cancer therapyMulti-modal strategies for overcoming tumor drug resistance: hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnology.Angiostatic treatment prior to chemo- or photodynamic therapy improves anti-tumor efficacy.Comparison of CVF (Cyclophosphamide+Vinorelbine+5-Fluorouracil) and CMF (Cyclophosphamide+Methotrexate+5-Fluorouracil) Adjuvant Chemotherapy in Early Breast Cancer.Ketorolac salt is a newly discovered DDX3 inhibitor to treat oral cancer.Methyl Sulfone Blocked Multiple Hypoxia- and Non-Hypoxia-Induced Metastatic Targets in Breast Cancer Cells and Melanoma CellsResistance to cancer chemotherapy: failure in drug response from ADME to P-gp.Hypoxia-induced autophagy mediates cisplatin resistance in lung cancer cells.Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancerTumor priming by Apo2L/TRAIL reduces interstitial fluid pressure and enhances efficacy of liposomal gemcitabine in a patient derived xenograft tumor model.Hypoxia-inducible factor 1α promotes primary tumor growth and tumor-initiating cell activity in breast cancerPretreatment diffusion-weighted and dynamic contrast-enhanced MRI for prediction of local treatment response in squamous cell carcinomas of the head and neckRole of heparan sulfatases in ovarian and breast cancer.Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy.Expression of aldehyde dehydrogenase after neoadjuvant chemotherapy is associated with expression of hypoxia-inducible factors 1 and 2 alpha and predicts prognosis in locally advanced breast cancerHypoxia counteracts taxol-induced apoptosis in MDA-MB-231 breast cancer cells: role of autophagy and JNK activationDevelopment of EGFR-targeted polymer blend nanocarriers for combination paclitaxel/lonidamine delivery to treat multi-drug resistance in human breast and ovarian tumor cells.Severe hypoxia induces chemo-resistance in clinical cervical tumors through MVP over-expression.
P2860
Q26775232-A2984854-B790-476D-8A22-4F6384B51FDCQ26783014-059EE9E6-60E0-4336-BE35-8A0D6F0E5228Q26800007-41426C6A-B6FA-447E-A230-6CAD827D2056Q28067724-63901110-FB25-4922-81A3-78745BABC931Q28248772-CDF9F86B-EECD-4368-8A9C-3D9A4265C936Q28384920-23CD1CF0-B230-437B-9FBD-630C05A22F87Q28396304-5C448B4B-E707-4729-9B68-98643C2DA84AQ28476850-6680589B-5CF7-41AB-9F81-3B8C7D137128Q28484877-6F752415-A186-4396-939A-CC8C04914A3FQ28833656-7EE7E344-AB32-4A99-9745-72F8AB11BC4DQ31144718-DFBEB202-49E9-4C35-91E3-15501849BA8CQ33671385-00EDBBB2-D690-4773-AA8D-6ECF4533072EQ33705108-1062F87F-695C-4856-9E15-8D627FE5127DQ33753431-AF9143F7-D1A7-43B5-9EBE-C7B79906D00FQ33781222-67C7DA0F-2238-43D2-8BD3-AA6D947B77F5Q34309899-E675E5CB-44BD-49DD-B83C-9666391EEBECQ34402422-8733C245-0F5B-47CA-ADF1-CEBCF8BADF55Q34407155-BC5B13CA-19F2-4A98-8E4D-60FDF63FF7FDQ34490253-BC880893-3592-4435-AA06-C75379FF9D69Q34610733-10536A59-ED6E-46E2-B970-5D7E8882B4C6Q34992476-84207664-5786-46A7-8B49-138215FA56D7Q35014428-C26992A1-4086-4BA6-B6C4-585EF04216ACQ35116993-C5B87A76-6B8A-4C84-958F-B5AD17207826Q35136562-CF462A0C-104E-4E5D-A193-B5FD2499B365Q35165488-905F939D-F3EA-441E-8468-2F3855953E44Q35435580-C5AB79FB-5C85-42E6-AF40-74C1B08A954FQ35545634-7A539961-8746-43B2-851B-BD4651C80564Q35831930-3E06E2E9-BED0-4A16-BF36-B94E393041E0Q35852614-347C2CB0-314F-4EE6-BC94-A6585F23DF7BQ35880778-4E165BEC-7F0E-441B-A2B6-47077BBB53ABQ36214623-D48D29D4-DF5D-425B-831C-249B2CE1F128Q36218165-6472A888-9478-46D1-8751-8BB34534A993Q36393103-25932644-FA4F-4ADF-8F91-B360CFE4213FQ36547400-49C8CA75-7DF7-46E4-90AC-CCDB935A7DCDQ36562888-49B310F1-A828-4983-A004-15D826CE200EQ36658463-BE21585C-4E79-42D2-84C4-761570ECF881Q36845043-7720095D-371C-4972-B448-3A83D306FCAAQ36907156-40978AB1-B96F-4D31-AB68-DA3680EC815AQ37280649-3D8C3874-8A8E-4CC4-885F-53BC567E6828Q37308405-4839201E-CF12-4F8F-98EE-9226C0B65CE7
P2860
Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Tumour hypoxia affects the res ...... d promotes cancer progression.
@en
Tumour hypoxia affects the res ...... d promotes cancer progression.
@nl
type
label
Tumour hypoxia affects the res ...... d promotes cancer progression.
@en
Tumour hypoxia affects the res ...... d promotes cancer progression.
@nl
prefLabel
Tumour hypoxia affects the res ...... d promotes cancer progression.
@en
Tumour hypoxia affects the res ...... d promotes cancer progression.
@nl
P1476
Tumour hypoxia affects the res ...... d promotes cancer progression.
@en
P2093
Jean-Philippe Cosse
P304
P356
10.2174/187152008785914798
P577
2008-10-01T00:00:00Z